Obinutuzumab
Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.
| ID | DRUG-OBINUTUZUMAB |
|---|---|
| Type | Drug |
| Aliases | GazyvaGazyvaroОбінутузумаб |
| Status | reviewed 2026-04-25 | pending_clinical_signoff |
| Diseases | DIS-CLL DIS-FL |
| Sources | SRC-ESMO-MZL-2024 SRC-NCCN-BCELL-2025 |
Drug Facts
| Class | Anti-CD20 monoclonal antibody (glycoengineered Type II) |
|---|---|
| Mechanism | Glycoengineered, humanized anti-CD20 monoclonal antibody; enhanced ADCC vs rituximab; greater direct cell death induction. |
| Typical dosing | 1000 mg IV per cycle (loading + maintenance schedule) |
| Ukraine registered | True |
| NSZU reimbursed | True |
| Ukraine last verified | 2026-04-27 |
Warnings
- Hepatitis B virus reactivation
- Progressive multifocal leukoencephalopathy
Notes
Alternative anti-CD20 for patients with rituximab intolerance, or in CLL/follicular lymphoma settings. Less established for MZL than rituximab; data extrapolated from CLL/FL trials.
Used By
Contraindications
CI-HBV-NO-PROPHYLAXIS- CI-HBV-NO-PROPHYLAXIS
Regimens
REG-AVO-CLL-1L- Acalabrutinib + Venetoclax + Obinutuzumab (AVO), fixed-duration 14 cycles (AMPLIFY)REG-O-CHL- Obinutuzumab + Chlorambucil (G-Clb, CLL11 — elderly comorbid CLL 1L)REG-OBINUTUZUMAB-BENDA- Obinutuzumab + Bendamustine (GADOLIN)REG-VENETOCLAX-OBINUTUZUMAB- Venetoclax + Obinutuzumab (VenO), 12 months fixed-duration (CLL14 schedule)REGIMEN-GLOFITAMAB-MONO-DLBCL-3L- Glofitamab IV monotherapy with obinutuzumab pretreatment, fixed-duration 12 cycles, for r...REGIMEN-GLOFITAMAB-OBINUTUZUMAB-PRETREATMENT- Obinutuzumab single-dose pretreatment 7 days before glofitamab cycle 1 (CRS mitigation)